Related Experiment Video
Updated: Jul 16, 2026
11:06
Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
Published on: April 7, 2023
Ezetimibe and fenofibrate combination therapy for mixed hyperlipidemia.
Yong S K Moon1, Patricia Chun, Suna Chung
1The University of the Pacific, Thomas J. Long School of Pharmacy and Health Sciences, Stockton, California, USA. yskmoon@earthlink.net
Drugs of Today (Barcelona, Spain : 1998)
|February 23, 2007
Summary
The U.S. FDA approved ezetimibe and fenofibrate combination therapy for mixed hyperlipidemia. This treatment effectively modifies lipids by targeting cholesterol and triglycerides, offering a new clinical option.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Mixed hyperlipidemia is a common condition characterized by elevated levels of both cholesterol and triglycerides.
- Current treatment guidelines aim to reduce cardiovascular risk by managing these lipid abnormalities.
Purpose of the Study:
- To review the recently approved combination therapy of ezetimibe and fenofibrate for mixed hyperlipidemia.
- To discuss the distinct mechanisms of action and synergistic effects of ezetimibe and fenofibrate.
Main Methods:
- Ezetimibe inhibits intestinal cholesterol absorption.
- Fenofibrate activates PPAR-alpha, influencing triglyceride metabolism.
- The combination leverages these complementary pathways for lipid modification.
Main Results:
- The combination therapy demonstrates potent synergistic actions on multiple lipid risk factors.
- Ezetimibe targets low-density lipoprotein cholesterol (LDL-C).
- Fenofibrate impacts very low-density lipoproteins (VLDL) and triglycerides.
Conclusions:
- Ezetimibe and fenofibrate combination therapy is a valuable new option for managing mixed hyperlipidemia with an excellent safety profile.
- Further research is needed to evaluate its use with other agents like statins and its impact on clinical outcomes.
- Outcome trials are warranted to assess the additive effects on morbidity and mortality.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:24Lipid Absorption
Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
01:06Lipid Digestion
Lipids are large molecules that are generally not water-soluble. Since most of the digestive enzymes in the human body are water-based, there are specific steps the body must take to break down lipids and make them available for use.
01:25Lipid Catabolism
Triglycerides serve as crucial long-term energy storage molecules in microorganisms, providing a dense source of metabolic energy. Their breakdown is mediated by lipases, which hydrolyze triglycerides into glycerol and free fatty acids. Each of these components follows distinct metabolic pathways, ultimately contributing to ATP synthesis and cellular energy homeostasis.Glycerol MetabolismGlycerol, released from triglyceride hydrolysis, is phosphorylated by glycerol kinase to form...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...